Early real-world data show that a single injection of the monoclonal antibody (mAb) nirsevimab (Beyfortus, Sanofi/AstraZeneca) was 83% effective in preventing babies from being hospitalized with lower respiratory tract disease caused by respiratory syncytial virus (RSV), according to French researchers (N Engl J Med 2024;391[2]:144-154).
Protection for a Vulnerable Population
RSV often causes severe illness, particularly in infants and young children. The previous RSV prophylaxis